Breztri Aerosphere for Asthma

Breztri Aerosphere (AstraZeneca), a three-drug inhaler containing the inhaled corticosteroid (ICS) budesonide, the long-acting antimuscarinic agent (LAMA) glycopyrrolate, and the long-acting beta2-agonist (LABA) formoterol fumarate, has been approved by the FDA for maintenance treatment of asthma in patients ≥12 years old. It was approved in 2020 for treatment of chronic obstructive pulmonary disease (COPD). Breztri Aerosphere is the second ICS/LAMA/LABA combination to become available for treatment of asthma. Trelegy Ellipta, which contains the ICS fluticasone, the LAMA umeclidinium, and the LABA vilanterol, is FDA-approved for maintenance treatment of asthma in adults.